Thyroid cancer (TC) is the most prevalent malignancy of the endocrine system. While most patients achieve favorable prognoses with early treatment, patients with advanced TC face a scarcity of effective therapeutic strategies. The thyroid gland is one of the most immunogenic tissues in the human body. With the deepening understanding of immune evasion mechanisms in TC and the application of immunotherapy in various solid malignancies, immune checkpoint therapy for TC has shown considerable therapeutic potential, offering new hope for patients with advanced TC. This paper focuses on summarizing the latest advancements in immune checkpoint therapy for TC, aiming to provide new directions for future research.

Thyroid cancer (TC) is the most prevalent malignancy of the endocrine system. While most patients achieve favorable prognoses with early treatment, patients with advanced TC face a scarcity of effective therapeutic strategies. The thyroid gland is one of the most immunogenic tissues in the human body. With the deepening understanding of immune evasion mechanisms in TC and the application of immunotherapy in various solid malignancies, immune checkpoint therapy for TC has shown considerable therapeutic potential, offering new hope for patients with advanced TC. This paper focuses on summarizing the latest advancements in immune checkpoint therapy for TC, aiming to provide new directions for future research.

Objective:To investigate the distribution patterns of TCM syndrome elements and syndrome types in cancer-related fatigue (CRF).Methods:A cross-sectional survey was conducted on tumor patients attending the outpatient clinic and wards of the Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences from January to December 2021. Descriptive analysis was used to compare the distribution difference of TCM syndrome elements, symptoms and tongue symptoms of CRF and non-CRF patients. The TCM symptoms of CRF were clustered to summarize the common TCM syndromes of CRF.Results:A total of 306 tumor patients were finally included, of which 229 (75%) were CRF and 77 (25%) were non-CRF. Qi deficiency, blood deficiency, and cold-dampness were the most common deficiency and excess syndrome elements in CRF, and liver deficiency, yin deficiency, and blood stasis syndrome elements occurred more frequently in non-CRF than in CRF. TCM symptoms with a frequency greater than 50% in CRF patients, from high to low, were: fatigue > shortness of breath > insomnia or dreaminess > mental fatigue > forgetfulness>lazy speech > impatience, irritability, depression with sighing. The most frequent tongue symptoms, tongue coating, and pulse symptoms were respectively pale tongue, white and greasy coating or smooth white, and pulse deficiency. The symptoms with greater than 30% frequency in 77 non-CRF patients were, from highest to lowest: impatience and irritability or depression with sighing > insomnia or dreaminess > shortness of breath > dry mouth and throat > lumbar spine pain (excluding traumatic) > numbness of limbs > forgetfulness. The highest-ranked tongue, tongue coating, and pulse symptoms were pale tongue, red tongue or less coating, no coating, and thin pulse, respectively. Through clustering analysis, six common syndromes of CRF were obtained, including qi and blood deficiency syndrome, heart and liver blood deficiency syndrome, kidney yang deficiency syndrome, qi and yin deficiency syndrome, spleen deficiency and qi stagnation syndrome, and cold dampness and spleen stagnation syndrome.Conclusions:CRF is a common symptom of different types of tumors. Generally, deficiency syndrome is the main symptom. Qi deficiency and blood deficiency are the common syndrome elements. Common symptoms of high frequency and tongue and pulse are fatigue, shortness of breath, mental fatigue, forgetfulness, pale tongue and thin pulse. The common TCM syndrome types can be preliminarily summarized into 6 types: qi and blood deficiency syndrome, heart and liver blood deficiency syndrome, kidney yang deficiency syndrome, qi and yin deficiency syndrome, spleen deficiency and qi stagnation syndrome, cold dampness and spleen stagnation syndrome.

Enhancing remyelination after injury is of utmost importance for optimizing the recovery of nerve function. While the formation of myelin by Schwann cells (SCs) is critical for the function of the peripheral nervous system, the temporal dynamics and regulatory mechanisms that control the progress of the SC lineage through myelination require further elucidation. Here, using in vitro co-culture models, gene expression profiling of laser capture-microdissected SCs at various stages of myelination, and multilevel bioinformatic analysis, we demonstrated that SCs exhibit three distinct transcriptional characteristics during myelination: the immature, promyelinating, and myelinating states. We showed that suppressor interacting 3a (Sin3A) and 16 other transcription factors and chromatin regulators play important roles in the progress of myelination. Sin3A knockdown in the sciatic nerve or specifically in SCs reduced or delayed the myelination of regenerating axons in a rat crushed sciatic nerve model, while overexpression of Sin3A greatly promoted the remyelination of axons. Further, in vitro experiments revealed that Sin3A silencing inhibited SC migration and differentiation at the promyelination stage and promoted SC proliferation at the immature stage. In addition, SC differentiation and maturation may be regulated by the Sin3A/histone deacetylase2 (HDAC2) complex functionally cooperating with Sox10, as demonstrated by rescue assays. Together, these results complement the recent genome and proteome analyses of SCs during peripheral nerve myelin formation. The results also reveal a key role of Sin3A-dependent chromatin organization in promoting myelinogenic programs and SC differentiation to control peripheral myelination and repair. These findings may inform new treatments for enhancing remyelination and nerve regeneration.
Animals ; Axons ; Chromatin/metabolism* ; Gene Expression Profiling ; Myelin Sheath/metabolism* ; Nerve Regeneration/physiology* ; Rats ; Schwann Cells/metabolism* ; Sciatic Nerve/injuries*

Objective To review the research progress, present the research status and analyze the evolution trend of hot spots through the bibliometric analysis of the research literature of cancer-related fatigue(CRF) at home and abroad. Methods We took CRF as the theme and the papers on CRF included in CNKI and WOS core database as the research object, and used VOSviewer and CiteSpace software as research tools, to make a visual atlas analysis on the research status and hot spot evolution at home and abroad. Results (1)Research status: ① Literature: 3 646 papers (1 959 in English and 1 687 in Chinese) were finally included. The number of papers published at home and abroad showed an overall upward trend, and the proportion of foreign fund papers was high; ② domestic papers focused on nursing and rehabilitation. The research area of foreign papers was more extensive, diverse and integrated; ③ Domestic cooperation was mainly small group cooperation, while foreign cooperation was more interdisciplinary and cross-team cooperation, forming a number of core teams and research institutions; ④ Domestic scholars paid attention to clinical application research and were good at learning from foreign countries and summarizing own experience. Foreign scholars paid more attention to basic research and the treatment was more systematic and standardized; ⑤ There were a variety of diagnostic and therapeutic evaluation tools, mainly foreign scales. (2) Hot spot evolution: "quality of life" had always been a common topic of concern at home and abroad. Domestic scholars focused on clinical research and emphasized "treatment based on examination of causes" and "treatment based on syndrome differentiation". Foreign scholars attached importance to basic research and methodological research, and advocated non-drug intervention such as sports. In recent years, complementary and alternative medicine had become a hot topic in the international research. Domestic scholars had paid more attention to the research of mechanism and methodology, and expanded the application of TCM characteristic therapy in CRF. Conclusion Integrated traditional Chinese and Western medicine and multi-disciplinary participation are the future diagnosis and treatment mode of CRF. It's the direction of future efforts to establish CRF evaluation and management mode with TCM characteristic non-drug therapy as the core under integrated medicine.

OBJECTIVE：To invest igtae the rationality of drug use of pregnant women in the outpatient department of our hospital，and to promote rational drug use in the clinic. METHODS ：The prescriptions of pregnant women in Beijing Shijitan Hospital Affiliated to Capital Medical University from Jan. to Dec. in 2019 were extracted by using hospital information management system ，and then analyzed statistically in respects of drug varieties ，DDDs，safety grading ，and use of Chinese patent medicine. RESULTS ：The most frequently used drugs in obstetric outpatients were vitamins and microelements ，followed by blood system and hormone drugs. Grade B drugs with good safety were most used ，the use of ungraded drugs were reasonable ，and grade X drugs were not used. There were 6 kinds of Chinese patent medicines used for pregnant women ，of which 2 kinds were marked “usable”in the drug instructions ，4 kinds were not marked in the dug instructions ，and the Chinese patent medicines that were not marked“prohibited”and“cautious”in the drug instructions were not used. CONCLUSIONS ：The drug use of pregnant women are generally reasonable in outpatient department of our hospital. The safety of some Chinese patent medicine used during pregnancy still needs to be further confirmed.

Objective:To investigate the effects of Jianpijiedutang combined with Kangfuxin Liquid in the treatment of recurrent oral ulcer(ROU).Methods:80 patients with ROU were divided into 2 groups(n=40).The patients in control group were treated with Kangfuxin Liquid local spray,those in the test group were treated with Jianpijiedutang combined with Kangfuxin Liquid spray.The patients were followed up for 24 weeks.The effects were evaluated according to the trial standard of Chinese Stomatological Association.Results:The interval of ROU increased and ulcer number decreased in the 2 groups during the observation period,the test group showed more effective outcome than the control group(P<0.05).In the treatment group ROU interval increased more than in the control group(P<0.01),and ROU ulcer number decreased more(P<0.01).Conclusion:The Jianpijiedutang combined with Kangfuxin Liquid spray is more effective than the latter used only.

Background and objective Status of epidermal growth factor receptor (EGFR) gene is a predictor of response to EGFR tyrosine kinase inhibitor (TKI). However, lile is know about the relationship between EGFR status and response to chemotherapy. We evaluated the prediction value of EGFR mutation status on response to first-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). Methods e data of 181 patients with stage IIIb/IV NSCLC who diagnosed by histopathology from January 10, 2006 to December 20, 2013 in Beijing Chest Hospital, Capital Medical University were collected. e relationships between EGFR gene status, clinical characteristics and response and progression-free survival (PFS) were analyzed. Results All of the 181 patients’ EGFR statuses were determined. 75 (41.4%) patients har-bored EGFR-activating mutations and 106 (58.6%) patients were EGFR wild-type. All patients received first-line chemother-apy. e objective response rate (ORR) was 26.0% and disease control rate (DCR) was 70.2%. Patients with EGFR-activating mutations had a higher DCR than patients with EGFR wild-type (84.0% vs 60.4%, P=0.001) did. Subgroup analysis showed that the ORR and DCR in patients with EGFR exon 19 deletions were remarkably higher than those with EGFR wild-type (P= 0.049, 0.002, respectively). e DCR in patients with EGFR exon 21 L858R mutation was significantly higher than that in patients with EGFR wild-type (P=0.010). 168 patients were available for response evaluation in all of 181 patients and median PFS was 4.3 mo. e PFS of patients with adenocarcinoma was significantly higher than that patients with squamous cell carci-noma (4.7 mo vs 3.0 mo, P=0.036). e PFS in patients harbored EGFR-activating mutations was significantly higher than that in the patients with EGFR wild-type (6.3 mo vs 3.0 mo, P=0.002). e PFS of patients with a performance status (PS) of 0-1 was significantly higher than that in patients with a PS of 2 (4.4 months vs. 0.7 months, P= 0.016). Cox multivariate analysis indicates the EGFR-activating mutation is an independent factor aecting PFS (HR=0.654, 95%CI: 0.470-0.909, P=0.012). Conclusion EGFR-activating mutation is a predictor for PFS of first-line chemotherapy in advanced NSCLC patients.

To analyze the distribution of traditional Chinese medicine constitution types in elderly patients with insomnia.

BACKGROUND AND OBJECTIVEResults of studies on genetic polymorphisms of ERCC1 gene in DNA repair pathway which may affect response to platinum-based chemotherapy and survival in patients with non-small cell lung cancer are conflicting. The aim of this study is to prospectively assess the association between single nucleotide polymorphisms of C8092A and codon118 in ERCC1 and drug response in 90 patients with advanced non-small cell lung cancer treated with cisplatin-based chemotherapy.

METHODSAll patients were treated with cisplatin-based chemotherapy. Genotypes of ERCC1 C8092A and codon118 were examined by sequencing, and the association between genotypes and response was evaluated.

RESULTSGenotype frequencies of ERCC1 C8092A were CC 40.0% (36/90), CA 48.9% (44/90) and AA 11.1% (10/90), frequencies of codon118 were CC 58.9% (53/90), CT 34.4% (31/90) and TT 6.7% (6/90). There was no significant difference in response rate of patients carrying with CC, compared with CA plus AA in C8092A (33.3% vs 29.6%, P = 0.71). Response rate of patients carrying with CC in ERCC1 118 was 32.1%, 24.3% with CT plus CC (P = 0.43). There was no difference in progression free survival between patients carrying with CC and CT plus TT in C8092A (5.2 months vs 5.4 months, P = 0.62). There was no difference in progression free survival between patients carrying with CC and CA plus AA (5.5 months vs 5.3 months, P = 0.59).

CONCLUSIONThe results suggest that there is no association between polymorphisms in ERCC1 C8092A and codon118 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy.

Adult ; Aged ; Antineoplastic Agents ; therapeutic use ; Carcinoma, Non-Small-Cell Lung ; drug therapy ; genetics ; mortality ; Cisplatin ; therapeutic use ; DNA-Binding Proteins ; genetics ; Disease-Free Survival ; Endonucleases ; genetics ; Female ; Genotype ; Humans ; Lung Neoplasms ; drug therapy ; genetics ; mortality ; Male ; Middle Aged ; Polymorphism, Genetic ; genetics ; Prospective Studies